Exactech Goes Private in $625M Deal With TPG Capital Post author:Sam Post published:October 22, 2017 Post category:BioPharma TPG Capital has acquired all the outstanding shares of Exactech common stock for $42 per share. Source: BioSpace You Might Also Like Infinity Pharma And Bristol-Myers Squibb Expand Clinical Collaboration Evaluating IPI-549 In Combination With Opdivo (Nivolumab) September 24, 2017 Ablynx Drug Fails Again in Mid-Stage Trial March 25, 2018 Takeda CEO Actively Hunts for Deals, Looks to Shed Non-Core Businesses November 16, 2017
Infinity Pharma And Bristol-Myers Squibb Expand Clinical Collaboration Evaluating IPI-549 In Combination With Opdivo (Nivolumab) September 24, 2017